BiotechTube

V116 + PPSV23

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumococcal Disease

Conditions

Pneumococcal Disease

Trial Timeline

Nov 7, 2022 → Feb 7, 2025

NCT ID
NCT05569954

About V116 + PPSV23

V116 + PPSV23 is a phase 3 stage product being developed by Merck for Pneumococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05569954. Target conditions include Pneumococcal Disease.

What happened to similar drugs?

15 of 20 similar drugs in Pneumococcal Disease were approved

Approved (15) Terminated (1) Active (5)
✅PNEUMOVAX™ 23MerckApproved
✅Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
✅21-valent pneumococcal conjugate vaccineMerckApproved
✅ProDiax-23 (PPSV23)MerckApproved
✅13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerApproved
✅pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
✅pneumococcus conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06177912Phase 3Completed
NCT05633992Phase 3Completed
NCT05569954Phase 3Completed
NCT05464420Phase 3Completed

Competing Products

20 competing products in Pneumococcal Disease

See all competitors
ProductCompanyStageHype Score
V114 + QIV + Matching Placebo for V114MerckPhase 3
40
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
40
V114 Lot 1 + V114 Lot 2 + Prevnar 13™MerckPhase 2
35
PNEUMOVAX™ 23MerckApproved
43
Pneumococcal Vaccine, Polyvalent (23-valent)MerckPhase 3
40
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
40
V114 + Prevnar 13®MerckPhase 3
40
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™MerckPhase 1/2
32
V116 + PPSV23MerckPhase 3
40
V114MerckPhase 3
40
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™MerckPhase 3
40
V114 + Prevnar 13®MerckPhase 3
40
Pneumococcal Conjugate Vaccine (V114) + PNEUMOVAX® 23 + PREVNAR 13®MerckPhase 2
35
V114-A + V114-B + Prevnar 13®MerckPhase 2
35
V116 + Pneumovax™23MerckPhase 1/2
32
V114 + Prevnar 13™MerckPhase 3
40
V114 + Prevnar 13™MerckPhase 2
35
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
43
21-valent pneumococcal conjugate vaccineMerckApproved
50
V116 + PPSV23MerckPhase 3
40